Importance of four-dimensional computed tomography simulation in locally advanced lung cancer radiotherapy: impact on reducing planning target volume

Slavica  Marić; Petar Janjić; Borut  Bosančić; Milan Mijailović; Snežana Lukić

doi:10.2298/VSP210520096M

Slavica Marić International Medical Centers Banja Luka – Affidea (IMC/Affidea), Banja Luka, Republic of Srpska, Bosnia and Herzegovina
Petar Janjić International Medical Centers Banja Luka – Affidea (IMC/Affidea), Banja Luka, Republic of Srpska, Bosnia and Herzegovina
Borut Bosančić University of Banja Luka, Faculty of Agriculture, Department of Biometrics, Institute of Genetic Resources, Banja Luka, Republic of Srpska, Bosnia and Herzegovina
Milan Mijailović University of Kragujevac, Faculty of Medical Sciences, Department of Radiology, Kragujevac, Serbia
Snežana Lukić University of Kragujevac, Faculty of Medical Sciences, Department of Radiology, Kragujevac, Serbia

DOI: https://doi.org/10.2298/VSP210520096M

Keywords: adenocarcinoma;, carcinoma, squamous cell;, four- dimensional computed tomography;, lung neoplasms;, radiotherapy.

Abstract

Background/Aim. Four-dimensional (4D) computed tomography (CT) simulation is a useful tool for motion assessment in lung cancer radiotherapy. Conventional three-dimensional (3D) free-breathing (FB) simulation is static, with limited motion information on respiratory movements that can produce inaccuracies in the delineation process and radiotherapy planning. The aim of this study was to compare clinically significant differences between the target volumes defined on 3D CT vs. 4D CT simulation and the potential impact on the planning target volume (PTV), bearing in mind that a reduced PTV with precise coverage of the primary tumor is extremely important. In addition, quantification of movements of the primary tumor (gross tumor volume – GTV) was performed during 4D CT simulation on three axes: Z-superoinferior (SI), X-mediolateral (ML), and Y-anteroposterior (AP). Methods. This retrospective study evaluated 20 lung cancer patients who underwent CT simulation for radical radiotherapy treatment. FB 3D CT and 4D CT simulations were acquired for each patient in accordance with our institutional protocol. A volumetric comparison of radiation volumes defined on 3D CT vs. 4D CT simulation was done on the following: GTV 3D vs. internal GTV (IGTV) 4D and PTV 3D vs. internal PTV (IPTV) 4D. The comparison of GTV movement in the FB phase GTV (GTV FB), phase 0 (GTV 0), phase 50 (GTV 50), and phase maximum intensity projection (GTV MIP) was made with GTV FB as the basic value. The evaluation was made on all three axes. Results. The comparison of volumetric values between GTV 3D vs. IGTV 4D was 63.15 cm³ vs. 85.51 cm³ (p < 0.001), respectively. IGTV 4D was significantly larger than GTV 3D (p < 0.001). The mean value of equivalent spherical diameter (ESD) for PTV 3D vs. IPTV 4D was 8.44 cm vs. 7.82 cm (p < 0.001), respectively, and the mean value volume PTV 3D vs. IPTV 4D was 352.70 cm³ vs. 272.78 cm³ (p < 0.001), respectively. PTV 3D was significantly larger than IPTV 4D (p < 0.001). A statistically significant difference (p < 0.05) was identified in the deviation related to the Z-axis between the upper and lower lobe. Conclusion. 4D CT simulation-based delineation can reduce PTV compared to 3D simulation-based radiation therapy; therefore, it is a prerequisite for high-quality and precise radiation therapy treatment.

Author Biography

Slavica Marić, International Medical Centers Banja Luka – Affidea (IMC/Affidea), Banja Luka, Republic of Srpska, Bosnia and Herzegovina

radioterapija, radijacioni onkolog

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71(3): 209‒49.

2. Ettinger DS, Wood DE, Aisner LD, Akerley W, Bauman RJ, Bharat A, et al. NCCN guidelines Insights: Non-small cell lung cancer version 2.2021. J Natl Compr Canc Netw 2021; 19(3): 254‒66.

3. International Association for the Study of Lung. Staging Manual in Thoracic Oncology. 2nd ed. North Fort Myers, FL: IASLC; 2016.

4. Park K, Vansteenkiste J, Lee HK,Peters S, Toshino J, Douillard JY. Pan - Asian adapted ESMO Clinical Practical Guidelines for the management of patients with locally advanced unresectable non-small lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOSS. Ann Oncol 2020; 31(2): 191‒201.

5. Fromm S, Rottenfusser, Berger D, Pirker R, Pötter R, Pokrajac B. 3D conformal radiotherapy for inoperable non-small cell lung cancer- a single center experience. Radiol Oncol 2007; 41(3): 133‒43.

6. Dhont J, Harden SV, Chee LYS, Aitken K, Hanna GG, Bertholet J. Image-guided Radiotherapy to Manage Respiratory Motion: Lung and Liver. Clin Oncol (R Coll Radiol) 2020; 32(12): 792‒804.

7. Boyle J, Ackerson B, Gu L, Kelsey CR. Dosimetric advantages of intensity modulated radiation therapy in locally advanced lung cancer. Adv Radiat Oncol 2017; 2(1): 6‒11.

8. Steiner E, Shieh CC, Caillet V, Booth J, O'Brien R, Briggs A, et al. Both four-dimensional computed tomography and four-dimensional cone beam computed tomography under-predict lung target motion during radiotherapy. Radiother Oncol 2019; 135: 65‒73.

9. Ono T, Nakamura M, Hirose Y, Kitsuda K, Ono Y, Ishigaki T, et al. Estimation of lung tumor position from multiple anatomical features on 4D-CT using multiple regression analysis. J Appl Clin Med Phys 2017; 18(5): 36‒42.

10. Ren XC, Liu YE, Li J, Lin Q. Progress in image-guided radiotherapy for the treatment of non-small cell lung cancer. World J Radiol 2019; 11(3): 46‒54.

11. Cusumano D, Dhont J, Boldrini L, Chiloiro G, Teodoli S, Massacessi M, et al. Predicting tumor motion during the whole radiotherapy treatment: a systematic approach for thoracic and abdominal lesions based on real time MR. Radiother Oncol 2018; 129(3): 456‒62.

12. Chavaudra J, Bridier A. Definition of volumes in external radiotherapy: ICRU reports 50 and 62. Cancer Radiother 2001; 5(5): 472‒8. (French)

13. International Commission on Radiation Units and Measurements. Prescribing, recording and reporting photon beam intensity modulated radiation therapy. ICRU report 83. Bethesda, MD: ICRU; 2010.

14. Giraud P, Antoine M, Larrouy A, Milleron B, Callard P, De Rycke Y, et al. Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. Int J Radiat Oncol Biol Phys 2000; 48(4): 1015‒24.

15. Kong FM, Ritter T, Quint DJ, Senan S, Gaspar LE, Komaki RU, et al. Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus. Int J Radiat Oncol Biol Phys 2011; 81(5): 1442‒57.

16. Mercieca S, Belderbos JSA, van Herk M. Challenges in the target volume definition of lung cancer radiotherapy. Transl Lung Cancer Res 2021; 10(4): 1983‒98.

17. Nestle U, Le Pechoux C, De Ruysscher D. Evolving target volume concepts in locally advanced non-small cell lung cancer. Transl Lung Cancer Res 2021; 10(4): 1999‒2010.

18. Wilke L, Andratschke N, Blanck O, Brunner TB, Combs SE, Grosu AL, et al. ICRU report on prescribing, recording and reporting of stereotactic treatments with small beam photons:Statements from DEGRO/DGMP working group stereotactic radiotherapy and radiosurgery. Strahlenter Onkol 2019; 195(3): 193‒8.

19. Ahmed N, Venkataraman S, Johnson K, Sutherland K, Loewen SK. Does Motion Assessment With 4-Dimensional Computed Tomographic Imaging for Non-Small Cell Lung Cancer Radiotherapy Improve Target Volume Coverage? Clin Med Insights Oncol 2017; 11: 1179554917698461.

20. Siow T, Lim S. Correlating lung tumor location and motion with respiration using 4DCT scan. J Radiother Pract 2021; 20(1): 17‒21.

21. Molitoris JK, Diwanji T, Snider JW 3rd, Mossahebi S, Samanta S, Badiyan SN, et al. Advances in the use of motion management and image guidance in radiation therapy treatment for lung cancer. J Thorac Dis 2018; 10(Suppl 21): S2437‒50.

22. Diwanji TP, Mohindra P, Vyfhuis M, Snider JW 3rd, Kalavagunta C, Mossahebi S, et al. Advances in radiotherapy techniques and delivery for non-small cell lung cancer: benefits of intensity-modulated radiation therapy, proton therapy, and stereotactic body radiation therapy. Transl Lung Cancer Res 2017; 6(2): 131‒47.

23. Chun SG, Hu C, Choy H, Komaki RU, Timmerman RD, Schild SE, et al. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. J Clin Oncol 2017; 35(1): 56‒62.

24. Ueyama T, Arimura T, Takumi K Nakamura F, Higashi R, Ito S, et al.. Risk factors for radiation pneumonitis after stereotactic radiation therapy for lung tumors: clinical usefulness of the planning target volume to total lung volume ratio. Br J Radiol 2018; 91(1086): 20170453.

25. Meng Y, Yang H, Wang W, Tang X, Jiang C, Shen Y, et al. Excluding PTV from lung volume may better predict radiation pneumonitis for intensity modulated radiation therapy in lung cancer patients. Radiat Oncol 2019: 14(7): doi.org/10.1186/s13014-018-120-x.

26. Matsuo Y, Shibuya K, Nakamura M, Narabayashi M, Sakanaka K, Ueki N, et al.. Dose volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys 2012; 83(4): e545‒9.

27. Seppenwoolde Y, Shirato H, Kitamora K, Shimizu S, van Herk M, Lebesque JV, et al. Precise and real-time measurement of 3-D tumor motion in lung due to breathing and heartbeat, measured during radiotherapy. Int J Radiat Oncol Biol Phys 2002; 53(4): 822‒34

28. Knybel L, Cvek J, Molenda L, Stieberova N, Feltl D. Analysis of Lung Tumor Motion in a Large Sample: Patterns and Factors Influencing Precise Delineation of Internal Target Volume. Int J Radiat Oncol Biol Phys 2016; 96(4): 751‒8.